The Center of Molecular Immunology (CIM) is a leading Cuban biotechnology institution focused on the research, development, and manufacturing of mammalian cell-based products. Established in 1994, it specializes in the production of monoclonal antibodies and therapeutic vaccines for cancer and autoimmune diseases. CIM is a key entity within the BioCubaFarma state group.
CIM is globally recognized for its innovative approach to 'active immunotherapy,' particularly its lung cancer vaccine CIMAvax-EGF. The center operates under high-quality standards (GMP) and has established international joint ventures and licensing agreements with partners in the United States, China, India, and Europe to bring its therapies to global markets.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:Unknown (State-owned)
Founded:1994
Ownership:government
Status:operating
FUNDING
Investors:Government of Cuba, BioCubaFarma
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (CIMAvax-EGF, Nimotuzumab)
Modalities:mAb, Therapeutic Vaccines, Recombinant Proteins
Active Trials:12
Trial Phases:Phase 1: 4 | Phase 2: 5 | Phase 3: 3 | Phase 4: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:BioCubaFarma
Subsidiaries:CIMAB S.A. (Commercial arm), Innovative Immunotherapy Alliance (Joint venture with Roswell Park), Biocubafarma China
Key Partnerships:Roswell Park Comprehensive Cancer Center (USA), Biocon (India), Kalbe Genexine Biologics (Indonesia), CIMYM BioSciences (Canada/Global)
COMPETITION
Position:Niche Player
Competitors:Merck (Keytruda), AstraZeneca (Tagrisso), Bristol Myers Squibb (Opdivo), Roche (Tecentriq)
LEADERSHIP
Key Executives:
Eduardo Ojito Magaz - Director General
Agustín Lage Dávila - Advisor / Former Director
Kalet León Monzón - Deputy Director
Scientific Founders:Agustín Lage Dávila
LINKS
Website:cim.sld.cu
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Center of Molecular Immunology (CIM). The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.